Adam M Leventhal1. 1. Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA; Department of Psychology, University of Southern California, Los Angeles, CA adam.leventhal@usc.edu.
Abstract
Efforts to reduce the public health burden of tobacco use have not equally benefited all members of society, leading to disparities in tobacco use as a function of ethnicity/race, socioeconomic position, physical/behavioral comorbidity, and other factors. Although multilevel transdisciplinary models are needed to comprehensively understand sources of tobacco-related health disparities (TRHD), the incorporation of psychopharmacology into TRHD research is rare. Similarly, psychopharmacology researchers have often overlooked the societal context in which tobacco is consumed. In an effort to facilitate transdisciplinary research agendas for studying TRHD and the psychopharmacology of tobacco use, this article introduces a novel paradigm, called "sociopharmacology." Sociopharmacology is a platform for investigating how contextual factors amplify psychopharmacological determinants of smoking to disproportionately enhance vulnerability to smoking in populations subject to TRHD. The overall goal of sociopharmacology is to identify proximal person-level psychopharmacological mechanisms that channel distal societal-level influences on TRHD. In this article I describe: (1) sociopharmacology's overarching methodology and theoretical framework; (2) example models that apply sociopharmacology to understand mechanisms underlying TRHD; (3) how sociopharmacological approaches may enhance the public health impact of basic research on the psychopharmacology of tobacco use; and (4) how understanding sociopharmacological mechanisms of TRHD might ultimately translate into interventions that reduce TRHD.
Efforts to reduce the public health burden of tobacco use have not equally benefited all members of society, leading to disparities in tobacco use as a function of ethnicity/race, socioeconomic position, physical/behavioral comorbidity, and other factors. Although multilevel transdisciplinary models are needed to comprehensively understand sources of tobacco-related health disparities (TRHD), the incorporation of psychopharmacology into TRHD research is rare. Similarly, psychopharmacology researchers have often overlooked the societal context in which tobacco is consumed. In an effort to facilitate transdisciplinary research agendas for studying TRHD and the psychopharmacology of tobacco use, this article introduces a novel paradigm, called "sociopharmacology." Sociopharmacology is a platform for investigating how contextual factors amplify psychopharmacological determinants of smoking to disproportionately enhance vulnerability to smoking in populations subject to TRHD. The overall goal of sociopharmacology is to identify proximal person-level psychopharmacological mechanisms that channel distal societal-level influences on TRHD. In this article I describe: (1) sociopharmacology's overarching methodology and theoretical framework; (2) example models that apply sociopharmacology to understand mechanisms underlying TRHD; (3) how sociopharmacological approaches may enhance the public health impact of basic research on the psychopharmacology of tobacco use; and (4) how understanding sociopharmacological mechanisms of TRHD might ultimately translate into interventions that reduce TRHD.
Authors: Lynne Dawkins; Jane H Powell; Robert West; John Powell; Alan Pickering Journal: Psychopharmacology (Berl) Date: 2006-10-18 Impact factor: 4.530
Authors: Philip H Smith; Ju Zhang; Andrea H Weinberger; Carolyn M Mazure; Sherry A McKee Journal: Drug Alcohol Depend Date: 2017-07-10 Impact factor: 4.492
Authors: N J Doogan; M E Roberts; M E Wewers; C A Stanton; D R Keith; D E Gaalema; A N Kurti; R Redner; A Cepeda-Benito; J Y Bunn; A A Lopez; S T Higgins Journal: Prev Med Date: 2017-03-16 Impact factor: 4.018
Authors: Mariel S Bello; Raina D Pang; Karen L Cropsey; Michael J Zvolensky; Lorraine R Reitzel; Jimi Huh; Adam M Leventhal Journal: Nicotine Tob Res Date: 2015-10-18 Impact factor: 4.244
Authors: Philip H Smith; Andrew J Bessette; Andrea H Weinberger; Christine E Sheffer; Sherry A McKee Journal: Prev Med Date: 2016-07-26 Impact factor: 4.018
Authors: Lesia M Ruglass; James C Root; Naomi Dambreville; Alina Shevorykin; Noshin Haque; Vicki Sun; Christine E Sheffer; Robert D Melara Journal: J Natl Med Assoc Date: 2019-07-30 Impact factor: 1.798
Authors: Raina D Pang; Matthew G Kirkpatrick; Nicholas I Goldenson; Casey R Guillot; Adam M Leventhal Journal: Pharmacol Biochem Behav Date: 2016-03-04 Impact factor: 3.533